Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma

Power Life Sciences Inc.500 enrolled

Overview

The main reason for conducting this research is to gain a better understanding of why some people with cholangiocarcinoma are not able to participate in or complete clinical trials. Historically, certain groups of people have been more likely to participate in clinical trials, but there hasn't been much research to understand why this is the case. The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through. The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future cholangiocarcinoma patients during clinical trials.

Study Type

OBSERVATIONAL

Enrollment

500

Conditions

Cholangiocarcinoma

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient is at least 18 years of age * Participant has a diagnosis of Cholangiocarcinoma * Patient has self-identified as planning to enroll in an interventional Cholangiocarcinoma clinical trial * Patient must provide written informed consent Exclusion Criteria: * No diagnosis of Cholangiocarcinoma confirmed * Inability to perform regular electronic reporting * Women who are pregnant, intend to become pregnant, or are lactating * Patient does not understand, sign, and return consent form

Outcomes

Primary Outcomes

Rate of patients who decide to enroll in a Cholangiocarcinoma Clinical Study.